Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Virpax Pharmaceuticals, Inc. VRPX

Healthcare  —  Biotechnology
0.01 0.00 0.00% as of 24 Sep
Market cap
$160.0K
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Virpax Pharmaceuticals, Inc. (VRPX) Business Profile

Updated before January 2025

Company Overview

Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is a clinical-stage biopharmaceutical company focused on developing innovative non-opioid therapies for pain management and central nervous system (CNS) disorders. Founded in 2016 and headquartered in Berwyn, Pennsylvania, Virpax aims to address unmet medical needs by leveraging advanced drug delivery systems and proprietary technologies. The company is led by its founder and CEO, Anthony P. Mack, who brings extensive experience in the pharmaceutical and biotechnology sectors. Under his leadership, Virpax has established itself as a pioneer in the development of non-addictive pain management solutions.

Core Business Segments

Virpax Pharmaceuticals operates primarily in the following business segments:

Pain Management

Virpax is dedicated to developing non-opioid pain management solutions to combat the opioid crisis. Key products in this segment include:

  • Epoladerm: A topical diclofenac spray film designed for osteoarthritis pain. Epoladerm utilizes the company’s proprietary delivery system to enhance drug absorption and efficacy.
  • Probudur: A long-acting injectable bupivacaine liposomal gel for post-surgical pain management. Probudur aims to provide extended pain relief while reducing the need for opioid medications.

Central Nervous System (CNS) Disorders

Virpax is also focused on addressing CNS disorders through innovative drug delivery technologies. Key products include:

  • Envelta: A nasal spray formulation of enkephalin, a naturally occurring peptide, for the treatment of acute and chronic pain. Envelta is being developed in collaboration with the National Institutes of Health (NIH).
  • AnQlar: A novel antiviral barrier nasal spray designed to protect against respiratory infections, including COVID-19 and influenza.

Advanced Drug Delivery Technologies

Virpax leverages proprietary drug delivery platforms to enhance the efficacy and safety of its products. These technologies include spray film delivery systems, liposomal formulations, and intranasal delivery mechanisms.

Business Model

Virpax Pharmaceuticals operates as a clinical-stage company, focusing on research and development (R&D) to bring its innovative therapies to market. The company collaborates with academic institutions, government agencies, and contract research organizations (CROs) to advance its pipeline. Revenue generation is anticipated through licensing agreements, partnerships, and eventual product sales upon regulatory approval. Virpax’s business model emphasizes:

  • Innovation: Developing cutting-edge, non-opioid therapies to address unmet medical needs.
  • Collaboration: Partnering with leading research institutions and government agencies to accelerate product development.
  • Regulatory Milestones: Achieving FDA approvals and other regulatory clearances to bring products to market.

Strategic Direction

Virpax Pharmaceuticals has outlined a clear strategic vision for its future growth:

  • Pipeline Expansion: The company plans to advance its existing pipeline while exploring new therapeutic areas, particularly in pain management and CNS disorders.
  • Global Market Penetration: Virpax aims to expand its presence in international markets through strategic partnerships and licensing agreements.
  • Sustainability Goals: The company is committed to developing environmentally friendly drug delivery systems and reducing its carbon footprint.
  • Innovation in Drug Delivery: Virpax continues to invest in advanced drug delivery technologies to enhance patient outcomes and differentiate its products in the market.

Competitive Landscape

Virpax Pharmaceuticals operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Pacira BioSciences, Inc.: A leader in non-opioid pain management solutions, particularly with its flagship product, Exparel.
  • Heron Therapeutics, Inc.: Focused on developing treatments for pain and cancer care, including non-opioid pain management products.
  • Zogenix, Inc.: Specializes in therapies for CNS disorders, including rare diseases.
  • Collegium Pharmaceutical, Inc.: Develops and commercializes pain management products, including opioid alternatives.

Virpax differentiates itself through its focus on innovative drug delivery systems and its commitment to non-opioid therapies.

Risk Factors

Like any clinical-stage biopharmaceutical company, Virpax faces several risks:

  • Regulatory Risks: Delays or failures in obtaining FDA approvals could impact the company’s ability to bring products to market.
  • Market Dependence: Virpax’s success is heavily reliant on the commercial viability of its pipeline products.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers poses risks of delays or shortages.
  • Competition: The biopharmaceutical industry is highly competitive, with numerous established players and emerging startups.
  • Financial Risks: As a pre-revenue company, Virpax depends on external funding to sustain its operations and advance its pipeline.

Recent Developments

Virpax has made significant progress in recent years:

  • Epoladerm Clinical Trials: The company has initiated Phase II clinical trials for Epoladerm, targeting osteoarthritis pain.
  • NIH Collaboration: Virpax continues to collaborate with the NIH on the development of Envelta, a non-addictive pain management solution.
  • AnQlar Development: The company is advancing AnQlar as a potential antiviral barrier against respiratory infections, with promising preclinical results.
  • Strategic Partnerships: Virpax has entered into licensing agreements to expand its global footprint and accelerate product development.

Investment Considerations

Investors considering Virpax Pharmaceuticals should weigh the following factors:

Strengths

  • Innovative Pipeline: A robust pipeline of non-opioid therapies addressing significant unmet medical needs.
  • Experienced Leadership: A seasoned management team with a proven track record in the pharmaceutical industry.
  • Collaborative Approach: Partnerships with leading research institutions and government agencies.

Risks

  • Regulatory Uncertainty: The success of Virpax’s pipeline depends on obtaining FDA approvals.
  • Financial Dependence: As a pre-revenue company, Virpax relies on external funding, which may dilute shareholder value.
  • Market Competition: Intense competition from established players and emerging startups.

Conclusion

Virpax Pharmaceuticals, Inc. is well-positioned to address the growing demand for non-opioid pain management solutions and innovative CNS therapies. With a strong pipeline, advanced drug delivery technologies, and a collaborative approach, the company has the potential to make a significant impact in the biopharmaceutical industry. However, investors should carefully consider the regulatory, financial, and competitive risks associated with a clinical-stage company. As Virpax advances its pipeline and achieves key milestones, it is poised for future growth and market success.